Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models

International Journal of Cancer

Volumn 125, Issue 11, 2009, Pages 2711-2720

  Liu, Gongjie ^a   Taylor, Stacey A ^a   Marrinan, Cindy H ^a   Hsieh, Yunsheng ^a   Bishop, W Robert ^a   Kirschmeier, Paul ^a   Long, Brian J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Docetaxel; Farnesyltransferase inhibitor; Lonafarnib; Prostate cancer

Indexed keywords

DOCETAXEL; LONAFARNIB; ANTINEOPLASTIC AGENT; PIPERIDINE DERIVATIVE; PYRIDINE DERIVATIVE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CELL CYCLE PROGRESSION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG POTENTIATION; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; BLOOD; CELL CYCLE; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; MOUSE MUTANT; NEOPLASM; NUDE MOUSE; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; WESTERN BLOTTING;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HUMANS; MALE; MICE; MICE, NUDE; MICE, SCID; NEOPLASMS, HORMONE-DEPENDENT; PIPERIDINES; PROSTATIC NEOPLASMS; PYRIDINES; TAXOIDS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 70350733642     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.24644     Document Type: Article

References (40)

1. Grönberg H. Prostate cancer epidemiology. Lancet 2003;361:859-864
2. Cancer facts and figures. American Cancer Society, 2007.
3. Tannock IF, de Wit R, Berry WR, Horti J, Pluzanska A, Chi KM, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004;351:1502-1512 (Pubitemid 39315317)
4. Petrylak DP, Tangen CM, Hussain MHA, Lara PN, Jr, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004;351:1513-1520 (Pubitemid 39315318)
5. Bos JL. Ras oncogenes in human cancer: a review. Cancer Res 1989;49:4682-4689 (Pubitemid 19213607)
6. Adjei AA. Blocking oncogenic ras signaling for cancer therapy. J Natl Cancer Inst 2001;93:1062-1074
7. Basso AD, Kirschmeier P, Bishop WR. Thematic review series: lipid posttranslational modifications: farnesyl transferase inhibitors. J Lipid Res 2006;47:15-31.
8. Njoroge FG, Taveras AG, Kelly J, Remiszewski S, Mallams AK, Wolin R, Afonso A, Copper AB, Rane DF, Liu Y-T, Wong J, Vibulbhan B, et al. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent. J Med Chem 1998;41:4890-4902
9. Taveras AG, Kirschmeier P, Baum CM. Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations. Curr Top Med Chem 2003;3:1103-1114
10. Zhang FL, Kirschmeier P, Carr D, James L, Bond RW, Wang L, Patton R, Windsor WT, Syto R, Zhang R, Bishop WR. Characterization of Ha-ras. N-ras. Ki-Ras4A, and. Ki-Ras4B as in vitro substrates for farnesyl protein transferase and geranylgeranyl protein transferase type I. J Biol Chem 1997;272:10232-10239 (Pubitemid 27171703)
11. Whyte DB, Kirschmeier P, Hockenberry TN, Nunez-Oliva I, James L, Catino JJ, Bishop WR, Pai J-K. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J Biol Chem 1997;272:14459-14464 (Pubitemid 27232866)
12. Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, et al. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and Wap-ras transgenic mice. Cancer Res 1998;58:4947-4956
13. Liu G, Marrinan CH, Taylor SA, Black S, Basso AD, Kirschmeier P, Bishop WR, Liu M, Long BJ. Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336). Anticancer Drugs 2007;18:923-932 (Pubitemid 47220711)
14. Taylor SA, Marrinan CH, Liu G, Nale L, Bishop WR, Kirschmeier P, Liu M, Long BJ. Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo. Gynecol Oncol 2008;109:97-106.
15. Moasser MM, Sepp-Lorenzino L, Kohl NE, Oliff A, Balog A, Su D-S, Danishepsky SJ, Rosen N. Farnesyl transferase inhibitors cause enhanced mitotic sensitivity to taxol and epothilones. Proc Natl Acad Sci USA 1998;95:1369-1374 (Pubitemid 28103398)
16. Shi B, Yaremko B, Hajian G, Terracina G, Bishop WR, Liu M, Nielsen LL. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo. Cancer Chemother Pharmacol 2000;46:387-393 (Pubitemid 30839670)
17. Nakamura K, Yamaguchi A, Namiki M, Ishihara H, Nagasu T, Kowalczyk JJ, Garci AM, Lewis MD, Yoshimatsu K. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel. Oncol Res 2001;12:477-484 (Pubitemid 33791808)
18. Zhu K, Gerbino E, Beaupre DM, Mackley PA, Muro-Cacho C, Beam C, Hamilton AD, Lichtenheld MG, Kerr WG, Dalton W, Alsina M, Sebti SM. Farnesyltransferase inhibitor R115777 (Zarnestra. Tipifarnib) synergizes with paclitaxel to induce apoptosis and mitotic arrest and to inhibit tumor growth of multiple myeloma cells. Blood 2005;105:4759-4766
19. Kim ES, Kies MS, Fossella FV, Glisson BS, Zaknoen S, Statkevich P, Munden RF, Summey C, Pisters KMW, Papadimitrakopoulou V, Tighiouart M, Rogatko A, et al. Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma. Cancer 2005;104:561-569 (Pubitemid 41022814)
20. Rossner D, Hollwitz B, Schaff C, Ay A, Rinnau F, Lersch W, Kühnle H. The combination of paclitaxel and the farnesyltransferase inhibitor SCH 66336 in the treatment of metastatic breast cancer. A phase I/II study. Presented at the 27th Annual San Antonio Breast Cancer Symposium San Antonio, Texas, 2004 (abstract #1068).
21. Eskens FALM, Awada A, Cutler DL, de Jong MJA, Luyten GPM, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske A-R, Piccart M for the European Organization for Research and Treatment of Cancer Early Clinical Studies Group. Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to humans with advanced solid tumors. J Clin Oncol 2001;19:1167-1175
22. Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, et al. Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res 2004;10:2968-2976 (Pubitemid 38619672)
23. Ready NE, Lipton A, Zhu Y, Statkevich P, Frank E, Curtis D, Bukowski RM. Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors. Clin Cancer Res 2007;13:576-583 (Pubitemid 46225364)
24. Solit DB, She Y, Lobo J, Kris MG, Scher HI, Rosen N, Sirotnak FM. Pulsatile administration of the epidermal growth factor receptor inhibitor gefitinib is significantly more effective than continuous dosing for sensitizing tumors to paclitaxel. Clin Cancer Res 2006;11:1983-1989 (Pubitemid 40471864)
25. Fury MG, Solit DB, Su YB, Rosen N, Sirotnak FM, Smith RP, Azzoli CG, Gomez JE, Miller VA, Kris MG, Pizzo BA, Henry R, et al. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol 2007;59:467-475 (Pubitemid 46122325)
26. Riely GJ, Rizvi NA, Kris MG, Milton DT, Solit DB, Rosen N, Senturk E, Azzoli CG, Brahmer JR, Sirotnak FM, Seshan VE, Fogle M, et al. Randomized phase II study of pulse erlotinib before or after carboplatin and paclitaxel in current or former smokers with advanced non-small-cell lung cancer. J Clin Oncol 2009;27:264-270
27. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
28. Hsieh Y, Chintala M, Mei H, Agans J, Brisson JM, Ng K, Korfmacher WA. Quantitative screening and matrix effect studies of drug discovery compounds in monkey plasma using fast-gradient liquid chromatography/tandem mass spectrometry. Rapid Commun Mass Spectrom 2001;15:2481-2487 (Pubitemid 34024217)
29. Hsieh Y, Merkle K, Wang G, Brisson JM, Kormacher WA. High-performance liquid chromatography-atmospheric pressure photoionization/tandem mass spectrometric analysis for small molecules in plasma. Anal Chem 2003;75:3122-3127 (Pubitemid 36830442)
30. Feldman EJ, Cortes J, DeAngelo DJ, Holyoake T, Simonsson B, O'Brien SG, Reiffers J, Turner AR, Roboz GJ, Lipton JH, Maloisel F, Colombat P, et al. On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia. Leukemia 2008;22:1707-1711
31. Sirotnak FM, Sepp-Lorenzino L, Kohl NE, Rosen N, Scher HI. A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer Chemother Pharmacol 2000;46:79-83.
32. Sepp-Lorenzino L, Tjaden G, Moasser MM, Timaul N, Ma Z, Kohl NE, Gibbs JB, Oliff A, Rosen N, Scher HI. Farnesyl:protein transferase inhibitors as potential agents for the management of human prostate cancer. Prostate Cancer Prostatic Dis 2001;4:33-43. (Pubitemid 32366716)
33. Caraglia M, Marra M, Leonetti C, Meo G, D'Alessandro AM, Baldi A, Santini D, Tonini G, Bertieri R, Zupi G, Budillon A, Abbruzzese A. R115777 (Zarnestra)/Zoledronic acid (Zometa) cooperation on inhibition of prostate cancer proliferation is paralleled by Erk/Akt inactivation and reduced Bcl-2 and bad phosphorylation. J Cell Physiol 2007;211:533-543
34. McPherson RA, Conaway MC, Gregory CW, Yue W, Santen RJ. The novel ras antagonist, farnesylthiosalicylate acid, suppresses growth of prostate cancer in vitro. Prostate 2004;58:325-334 (Pubitemid 38295026)
35. Erlich S, Tal-Or P, Liebling R, Blum R, Karunagaran D, Kloog Y, Pinkas-Kramarski R. Ras inhibition results in growth arrest and death of androgen-dependent and androgen-independent prostate cancer cells. Biochem Pharmacol 2006;72:427-436 (Pubitemid 44061749)
36. Basso AD, Long B, Marrinan C, Liu G, Pai J, Oliva I, Liu M, Kirschmeier P, Bishop WR. SCH66336 (Lonafarnib), a farnesyl transferase inhibitor, enhances the apoptotic and anti-tumor response to docetaxel. Proc Am Assoc Cancer Res 2004;45: abstract #3866.
37. Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P. Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem 2000;275:30451-30457 (Pubitemid 30751364)
38. Schafer-Hales K, Iaconelli J, Snyder JP, Prussia A, Nettles JH, El-Naggar A, Khuri FR, Giannakakou P, Marcus AI. Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function. Mol Cancer Ther 2007;6:1317-1328 (Pubitemid 46711995)
39. Marcus AI, Zhou J, O'Brate A, Hamel E, Wong J, Nivens M, El-Naggar A, Yao TP, Khuri FR, Giannakakou P. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. Cancer Res 2005;65:3883-3893 (Pubitemid 40616370)
40. Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Ronald L, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol 2008;26:3204-3212